Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sham Mailankody

Showing results (81-90 of 174) with videos related to

Pageof 18
Sort By:
British Journal of Haematology|August 16, 2021
Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxisKatrina Piedra, Tim Peterson, Carlyn Tan, et al.
British Journal of Haematology|February 7, 2020
Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myelomaMarion Eveillard, Even Rustad, Mikhail Roshal, et al.
Leukemia & Lymphoma|December 3, 2016
Proteomic profiling in plasma cell disorders: a feasibility studySham Mailankody, Sean M Devlin, Neha Korde, et al.
Leukemia & Lymphoma|October 14, 2016
Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiencyAdebayo Ogunniyi, Mabel Rodriguez, Sean Devlin, et al.
Blood Advances|January 4, 2018
Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based studyMarianna Thordardottir, Ebba K Lindqvist, Sigrun H Lund, et al.
Haematologica|September 3, 2021
Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controlsUrvi A Shah, Sæmundur Rögnvaldsson, Andriy Derkach, et al.
Cancer Medicine|February 4, 2023
Clinical value of second opinions in oncology: A retrospective review of changes in diagnosis and treatment recommendationsAllison Lipitz-Snyderman, Susan Chimonas, Sham Mailankody, et al.
Transplantation|February 19, 2010
Epidemiology of infections requiring hospitalization during long-term follow-up of pancreas transplantationNassir Rostambeigi, Yogish C Kudva, Seby John, et al.
Leukemia & Lymphoma|August 10, 2017
Host-related immunodeficiency in the development of multiple myelomaTalib Dosani, Sham Mailankody, Neha Korde, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|February 5, 2021
Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapyMarion Eveillard, Neha Korde, Amanda Ciardiello, et al.
Pageof 18

Showing results (81-90 of 174) with videos related to

Sort By:
Pageof 18
British Journal of Haematology|August 16, 2021
Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxisKatrina Piedra, Tim Peterson, Carlyn Tan, et al.
British Journal of Haematology|February 7, 2020
Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myelomaMarion Eveillard, Even Rustad, Mikhail Roshal, et al.
Leukemia & Lymphoma|December 3, 2016
Proteomic profiling in plasma cell disorders: a feasibility studySham Mailankody, Sean M Devlin, Neha Korde, et al.
Leukemia & Lymphoma|October 14, 2016
Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiencyAdebayo Ogunniyi, Mabel Rodriguez, Sean Devlin, et al.
Blood Advances|January 4, 2018
Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based studyMarianna Thordardottir, Ebba K Lindqvist, Sigrun H Lund, et al.
Haematologica|September 3, 2021
Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controlsUrvi A Shah, Sæmundur Rögnvaldsson, Andriy Derkach, et al.
Cancer Medicine|February 4, 2023
Clinical value of second opinions in oncology: A retrospective review of changes in diagnosis and treatment recommendationsAllison Lipitz-Snyderman, Susan Chimonas, Sham Mailankody, et al.
Transplantation|February 19, 2010
Epidemiology of infections requiring hospitalization during long-term follow-up of pancreas transplantationNassir Rostambeigi, Yogish C Kudva, Seby John, et al.
Leukemia & Lymphoma|August 10, 2017
Host-related immunodeficiency in the development of multiple myelomaTalib Dosani, Sham Mailankody, Neha Korde, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|February 5, 2021
Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapyMarion Eveillard, Neha Korde, Amanda Ciardiello, et al.
Pageof 18